• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Endocare

Endocare

Endocan Corp ENDO

Last Price$0.02Day Change (%)-2.34%
Open Price$0.02Day Change ($)0.00
Day Range0.02–0.0252-Week Range0.02–0.18

As of Fri 12/26/2014 02:26 PM | USD

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain

    Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain

  2. Auxilium Announces Date for Special Meeting of Stockholders

    Auxilium Announces Date for Special Meeting of Stockholders

  3. Research and Markets: Global & USA Transdermal Drug Delivery Market to 2017

    Research and Markets: Global & USA Transdermal Drug Delivery Market to 2017

  4. Market bears fire shot across the bow

    Market bears fire shot across the bow

  5. Syneron Candela Signs Agreement with American Medical Systems to Supply Holmium Laser for Urology

    Syneron Candela Signs Agreement with American Medical Systems to Supply Holmium Laser for Urology

  6. The Market: Exaggerated Woes

    Endo Pharmaceuticals ENDP announced July 11 that it no longer expects to file a new drug application for its ketoprofen pain-relief patch by the first half of 2008 because of lackluster Phase III trial results. The drug candidate failed to show statistically significant results for pain relief in ...

  7. Salesforce Continues to Increase Investments in Japan

    Salesforce Continues to Increase Investments in Japan

  8. Research and Markets: BRIC Bariatric Surgery Devices Market Outlook to 2020: Key players covered include Covidien, Ethicon Endosurgery and Allergan

    Research and Markets: BRIC Bariatric Surgery Devices Market Outlook to 2020: Key players covered include Covidien, Ethicon Endosurgery and Allergan

  9. Research and Markets: Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2014

    Research and Markets: Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2014

  10. Research and Markets: Low Back Pain - Pipeline Review, H2 2014

    Research and Markets: Low Back Pain - Pipeline Review, H2 2014

12
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.